Effect of silver diamine fluoride with or without potassium iodide treatment on retention of composite resin restorations in carious primary molars- a randomized clinical trial.

J DentMay 22, 2026 (epub)
Clinical ResearchPediatrics

Amna Afrin Kidwai, Kalpana Bansal, Vijay Prakash Mathur et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized clinical trial evaluated the retention of composite resin restorations in carious primary molars among 150 children aged 4-9 years. The study compared the effects of silver diamine fluoride (SDF) with and without potassium iodide (KI) on restoration retention. At 12 months, retention rates were 76% for SDF + KI, 74% for SDF alone, and 72% for restorations without SDF, showing no significant differences (p = 0.53).

Key findings

  • At 12 months, retention rates were 76% for SDF + KI, 74% for SDF alone, and 72% for CRR alone.
  • Significant differences in colour match and marginal discoloration were observed between groups (p < 0.001).
  • No significant difference in secondary caries was found (p = 0.78).

Why it matters

The findings suggest that incorporating SDF into caries management protocols for primary molars does not compromise the retention of composite restorations. Improved aesthetics with SSKI may enhance patient satisfaction.

Source

Published in J Dent. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.